



EGeen RNA Program Country Card – Hungary



Hungary Overview



- Population: 9.88 million
- Five Largest Cities: Budapest, Debrecen, Miskolc, Szeged, Pecs
- Language: Hungarian
- EU Member: Yes (2004)
- Govt Type: Parliamentary Democratic Republic
- Govt. Admin.: 19 Counties + Budapest (capital)
- Health System: Universal healthcare, OEP insurance fund; private fee

Clinical Trial Network / Comments



- HC Sites: 99 hospitals, two national institutes, >650+ clinics; 7.00 beds per 1000
- HC Splits: 70% public / 30% private; 32% inpatient / 68% outpatient
- Investigators: ICH GCP experienced, high quality, motivated
- CRAs: Physicians, biologists, nurses; good relations with investigators
- High level of clinical trials amongst CEE countries; popular clinical trial country
- Higher than average lung and colon cancer rates; very high cardiovascular rates


EGeen Clinical Trial Support



- Full range of clinical trial services
- Patient recruitment, clinical monitoring, data management, biostatistics, regulatory
- Pharmacovigilance, project management, ethics review, quality assurance
- EU Qualified Person (QP) assistance to obtain EU GMP certificate for manufacturing reqs.
- Cost-effective EU / EE / non-EU importation partnerships and local IMP logistics
- Institutional relationships to proactively obtain contract approvals prior to regulatory filings as needed



Hungary – Clinical Trail Process Overview



Hungary Republic Approval Process Highlights



- Qualified Person (QP) must be identified and registered prior to approval process beginning
- CTA site contracts can be negotiated during RA, CEC approval process, saving time
- RA and CEC approvals can begin concurrently, saving time
- All major submission documents need to be in Hungarian language **NOTE**
- CEC reviews runs concurrently with RA reviews; may even finish earlier
- LEC reviews and approvals are absent **NOTE**
- IMP import license only required if imported from outside EU **NOTE**
- Summary: Time from QP ID to Importation of IMP estimated at **18 weeks**

Note: Summary time total is an estimated average of trial complexity